News & Analysis as of September 13, 2024

Regulatory Agenda

+ Follow

Medicaid is a partnership program between states and the federal government to provide healthcare coverage for lower income individuals, people with disabilities, older people, and certain families with... more +

Last Call for Comments on Bipartisan Discussion Draft SUSTAIN Act: Shaping 340B for the Future

Epstein Becker & Green on 3/26/2024

Only a few days remain for stakeholders—which includes drug manufacturers, patients, health care providers, pharmacies and others— to take advantage of a rare opportunity to influence the statutory contours of the 340B Drug...more

Healthcare Preview for the Week of: October 30, 2023

McDermott+ on 10/31/2023

NEXT UP: SPEAKER MIKE JOHNSON - The House officially has a speaker: Mike Johnson (R-LA). On October 25, Rep. Johnson became Speaker Johnson with a final vote on the first ballot of 220–209. Speaker Johnson, a...more

A Flurry of Recent Activity Highlights Continued Interest in 340B Program Oversight

Baker Donelson on 1/30/2020

Four separate government releases coming over a three-week period have once again highlighted the intense interest in the 340B drug pricing program, with a federal agency and two government watchdog groups issuing guidance...more

Regulatory Insights for Life Sciences and Health Care Investments: Drug Pricing and Reimbursement

Hogan Lovells on 11/30/2018

Investing in the life sciences industry without an understanding of the key regulatory factors that could determine a product's success or failure could cost you millions of dollars....more

Health Care Policy Newsletter

Foley & Lardner LLP on 5/14/2018

Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our second “Public Policy Weekly* Health Care Newsletter” in which we compile the latest health care policy news and legislation. Please...more

5 Results

View per page